PLUS1
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
|
After Hours Last Trade |
Last $ 140.98 ◊ 0.00 (0.00%) | |
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | JNJ | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.99 | 0.71% | 140.98 | 141.98 | 140.63 | 140.93 | 139.99 | 19:31:14 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 52,303 | 6,631,993 | $ 141.04 | $ 935,380,338 | 6,785,522 | 121.00 - 148.5899 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:55:47 | 8 | $ 141.25 | USD |
Johnson and Johnson Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 371.04B | 2.63B | $ 15.30B | 5.61 | 26.60 | 2.63B |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 16.45M | $ 3.54 | 2.51% | 11/25/19 | 1.00 | 0.10% |
Johnson and Johnson News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/10/2019 | 18:15 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 12/10/2019 | 18:15 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 12/10/2019 | 10:08 | PR Newswire (US) | Johnson & Johnson to Host Investor Conference Call on.. |
| 12/10/2019 | 08:20 | Dow Jones News | Amgen: Phase 3 Study Combining Kyprolis, Darzalex Met.. |
| 12/09/2019 | 10:52 | Dow Jones News | XBiotech Shares Jump After Selling Bermekimab to Janssen |
| 12/09/2019 | 06:55 | Dow Jones News | XBiotech Sells Bermekimad to Janssen Biotech |
| 12/08/2019 | 08:00 | PR Newswire (US) | Johnson & Johnson Announces Commitment to Support Republic.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical JNJ Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 138.50 | 141.98 | 137.16 | 139.88 | 5,552,951 | 2.48 | 1.79% |
| 1 Month | 131.04 | 141.98 | 130.14 | 136.82 | 6,455,495 | 9.94 | 7.59% |
| 3 Months | 129.90 | 141.98 | 126.10 | 132.50 | 7,339,478 | 11.08 | 8.53% |
| 6 Months | 139.83 | 144.98 | 124.56 | 133.05 | 7,311,762 | 1.15 | 0.82% |
| 1 Year | 146.29 | 148.5899 | 121.00 | 133.69 | 7,528,041 | -5.31 | -3.63% |
| 3 Years | 112.69 | 148.99 | 110.76 | 132.09 | 6,380,754 | 28.29 | 25.1% |
| 5 Years | 105.50 | 148.99 | 81.79 | 120.91 | 6,565,472 | 35.48 | 33.63% |
Johnson and Johnson Description
| Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States. |
